Two pathways: Serotonin versus kynurenine
Tryptophan is an amino acid with a critical metabolic split: roughly 5% of dietary tryptophan is converted to serotonin (via tryptophan hydroxylase and aromatic amino acid decarboxylase), while roughly 95% enters the kynurenine pathway, producing kynurenine metabolites involved in energy metabolism, immune signaling, and vitamin B3 synthesis.
Normally, this balance is tightly regulated. But during inflammation, infection, or immune activation, the enzyme indoleamine 2,3-dioxygenase (IDO) is induced by inflammatory cytokines like interferon-gamma and tumor necrosis factor-alpha. IDO diverts tryptophan toward kynurenine and away from serotonin. This metabolic bottleneck is now recognized as a mechanistic link between inflammation and depression.
The kynurenine-to-tryptophan ratio as a biomarker
The ratio of kynurenine to free tryptophan is an emerging clinical biomarker with growing evidence in psychiatry and inflammatory medicine. When IDO is activated by inflammation, this ratio rises — tryptophan decreases (substrate is being consumed) and kynurenine increases (product accumulates).
Elevated kynurenine-to-tryptophan ratios are associated with major depressive disorder, anxiety, fatigue, cognitive decline, and poor response to selective serotonin reuptake inhibitors (SSRIs). In autoimmune disease, chronic infection, and critical illness, this ratio often correlates with symptom severity and illness burden. For clinicians, this metric quantifies the degree to which inflammation is suppressing serotonin synthesis.
Beyond serotonin: The neuroactive metabolites
Kynurenine itself is not neurotoxic, but its downstream metabolites are. Quinolinic acid is an N-methyl-D-aspartate (NMDA) receptor agonist that can cause excitotoxicity and neuroinflammation. Kynurenic acid is an NMDA antagonist associated with cognitive dysfunction. The balance between these competing metabolites affects brain function and mood.
Dysbiosis and altered tryptophan metabolism have been associated with elevated quinolinic acid and decreased kynurenic acid, shifting the balance toward neuroinflammation. This metabolic imbalance is observed in depression, schizophrenia, and neurodegenerative conditions, making kynurenine pathway metabolites targets for novel psychiatric therapies.
Clinical applications: From diagnostics to intervention
Treatment-resistant depression (TRD). Patients whose depression doesn't respond to SSRIs often have elevated inflammatory markers and altered tryptophan metabolism. For these patients, measuring the kynurenine pathway alongside traditional markers helps identify whether inflammation is driving symptoms. Anti-inflammatory strategies (NSAIDs, exercise, dietary anti-inflammatory compounds) may be more effective than increasing serotonin reuptake inhibitor doses.
Autoimmune and inflammatory conditions. Rheumatoid arthritis, lupus, inflammatory bowel disease, and chronic viral infections often produce depressive and cognitive symptoms. Elevated kynurenine-to-tryptophan ratios may explain the neuropsychiatric complications of these conditions and could guide targeted interventions to reduce IDO activation.
Chronic fatigue and post-viral syndromes. Growing evidence links elevated kynurenine pathway activation and depleted tryptophan to the fatigue and brain fog seen in post-viral conditions and chronic fatigue syndrome. Measuring tryptophan and kynurenine metabolites helps confirm a metabolic basis for symptoms and guides nutritional and immune-modulating interventions.
Gut-brain axis and dysbiosis. The gut microbiome produces tryptophan metabolites and regulates the balance between serotonin and kynurenine pathways. Dysbiosis is associated with increased tryptophan degradation and elevated kynurenine. Microbiome-directed interventions (probiotics, fermented foods, dietary diversity) can restore this balance and improve mood and cognitive function.
What Masdiag measures from a dried blood spot
At Masdiag, we measure free tryptophan, kynurenine, serotonin, and related metabolites directly from a dried blood spot sample using LC-MS/MS. This enables rapid assessment of tryptophan pathway status, calculation of the kynurenine-to-tryptophan ratio, and detection of metabolic imbalances that may contribute to mood, cognitive, or inflammatory symptoms.
A single finger-prick sample provides enough material for comprehensive tryptophan pathway profiling at a fraction of the cost and complexity of serum sampling. Results are available within 5-7 days, enabling practitioners to integrate these findings into clinical decision-making and treatment planning.
Frequently asked questions
What is the kynurenine pathway and why does it matter for mental health?
The kynurenine pathway is an alternative route for tryptophan metabolism that competes with serotonin synthesis. When inflammation or immune activation is high, the enzyme IDO (indoleamine 2,3-dioxygenase) is induced, diverting tryptophan away from serotonin production and toward kynurenine metabolites. Elevated kynurenine and a high kynurenine-to-tryptophan ratio are associated with depression, anxiety, cognitive decline, and poor treatment response to antidepressants. This is why inflammatory states often co-occur with mood disorders.
Can tryptophan metabolites help explain treatment-resistant depression?
Yes. Many patients with treatment-resistant depression (TRD) have elevated inflammatory markers and altered tryptophan metabolism, particularly high kynurenine-to-tryptophan ratios and elevated neuroactive kynurenine metabolites like quinolinic acid. These findings suggest that inflammation-driven activation of the kynurenine pathway, rather than simple serotonin depletion, may drive symptoms in a subset of depressed patients. Identifying this metabolic pattern can guide anti-inflammatory or immune-modulating approaches alongside or instead of traditional SSRIs.
What role does the gut microbiome play in tryptophan metabolism?
Gut bacteria regulate tryptophan metabolism through multiple mechanisms: they produce tryptophan metabolites like indoles and aryl hydrocarbon receptor (AhR) agonists that influence immune tolerance and intestinal barrier integrity, and they influence the balance between serotonin and kynurenine pathways. Dysbiosis (altered bacterial composition) is associated with increased tryptophan degradation and skewed kynurenine pathway activation. This is the mechanistic basis of the 'gut-brain axis' and why gut health interventions (probiotics, dietary fiber, microbial diversity) can influence mood and mental health.
Explore Tryptophan Pathway Testing
Comprehensive tryptophan and kynurenine pathway profiling from dried blood spot. Ideal for assessing treatment-resistant depression, autoimmune conditions, and chronic inflammatory states.
Contact Us About Testing →